The Sensex was down 79.20 points at 27757.31 and the Nifty down 40.85 points at 8574.40.
The BSE Midcap and Smallcap indices were down more than 1 percent on weak breadth. About 1638 shares declined against 775 advancing shares on the exchange.
Tata Group stocks continued to reel under pressure and remained in the most active list due to ongoing Tata-Mistry issue. Tata Motors, Tata Steel and TCS fell 1-2 percent, continuing to fall for the third consecutive session.
Markets in Asia Pacific were mostly lower, with energy plays in the region under pressure after oil prices extended their losing streak during the US session.
Hong Kong's Hang Seng index slipped 1.07 percent. Chinese mainland shares traded lower, with the Shanghai composite down 0.17 percent. Japan's Nikkei 225 average was down 0.3 percent.
European stocks opened lower amid rising concerns that OPEC countries will not reach an agreement over a production cut and a raft of corporate earnings.
The Pan-European STOXX 600 index was down 0.18 percent.
Sun Pharma today said it has launched generic versions of Daiichi Sankyo medicines, used in treatment of high blood pressure, in the US market.
In a BSE filing, Sun Pharmaceutical Industries said "its wholly owned subsidiary has launched in US, the authorized generic versions for all strengths of Benicar, Benicar HCT, Azor and Tribenzor of Daiichi Sankyo Inc".
Four medicines include Olmesartan Medoxomil, Olmesartan Medoxomil-Hydrochlorothiazide, Amlodipine Besylate-Olmesartan Medoxomil and Amlodipine Besylate-Hydrochlorothiazide -Olmesartan Medoxomil tablets.
The launch is pursuant to a distribution and supply agreement between Sun Pharma's wholly owned subsidiary and Daiichi Sankyo Inc, which grants the Sun Pharma subsidiary, exclusive rights to distribute these tablets in the US for a pre-determined period.
Public sector lender Vijaya Bank showed stellar performance in July-September quarter with profit growing 34 percent year-on-year to Rs 154.5 crore on strong net interest income, other income and operational growth despite provisions remained at elevated level. Asset quality also improved.
Net interest income during the quarter grew by 19.5 percent to Rs 827.8 crore while non-interest income doubled to Rs 388.3 crore on yearly basis.
Operating profit reported a whopping 43 percent growth at Rs 570.9 crore compared with year-ago period.
The BSE Midcap and Smallcap indices were down more than 1 percent on weak breadth. About 1638 shares declined against 775 advancing shares on the exchange.
Tata Group stocks continued to reel under pressure and remained in the most active list due to ongoing Tata-Mistry issue. Tata Motors, Tata Steel and TCS fell 1-2 percent, continuing to fall for the third consecutive session.
Markets in Asia Pacific were mostly lower, with energy plays in the region under pressure after oil prices extended their losing streak during the US session.
Hong Kong's Hang Seng index slipped 1.07 percent. Chinese mainland shares traded lower, with the Shanghai composite down 0.17 percent. Japan's Nikkei 225 average was down 0.3 percent.
European stocks opened lower amid rising concerns that OPEC countries will not reach an agreement over a production cut and a raft of corporate earnings.
The Pan-European STOXX 600 index was down 0.18 percent.
Sun Pharma today said it has launched generic versions of Daiichi Sankyo medicines, used in treatment of high blood pressure, in the US market.
In a BSE filing, Sun Pharmaceutical Industries said "its wholly owned subsidiary has launched in US, the authorized generic versions for all strengths of Benicar, Benicar HCT, Azor and Tribenzor of Daiichi Sankyo Inc".
Four medicines include Olmesartan Medoxomil, Olmesartan Medoxomil-Hydrochlorothiazide, Amlodipine Besylate-Olmesartan Medoxomil and Amlodipine Besylate-Hydrochlorothiazide -Olmesartan Medoxomil tablets.
The launch is pursuant to a distribution and supply agreement between Sun Pharma's wholly owned subsidiary and Daiichi Sankyo Inc, which grants the Sun Pharma subsidiary, exclusive rights to distribute these tablets in the US for a pre-determined period.
Public sector lender Vijaya Bank showed stellar performance in July-September quarter with profit growing 34 percent year-on-year to Rs 154.5 crore on strong net interest income, other income and operational growth despite provisions remained at elevated level. Asset quality also improved.
Net interest income during the quarter grew by 19.5 percent to Rs 827.8 crore while non-interest income doubled to Rs 388.3 crore on yearly basis.
Operating profit reported a whopping 43 percent growth at Rs 570.9 crore compared with year-ago period.
No comments:
Post a Comment